Appropriate use of exercise testing prior to administration of drugs for treatment of erectile dysfunction

Herz

Volumn 28, Issue 4, 2003, Pages 291-297

  Arruda Olson, Adelaide M ^b   Pellikka, Patricia A ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic ^*

Author keywords

Erectile dysfunction; Exercise test; Ischmic heart disease; Phosphodiesterase inhibitors

Indexed keywords

GLYCERYL TRINITRATE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL;

ANGINA PECTORIS; DIAGNOSTIC VALUE; DRUG CONTRAINDICATION; ERECTILE DYSFUNCTION; EXERCISE TEST; HUMAN; ISCHEMIC HEART DISEASE; PRESCRIPTION; REVIEW;

EID: 0038267649     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-003-2477-9     Document Type: Review

References (47)

1. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU International 1999;84:50-6.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
3. Wei M, Macera CA, Davis DR, Ornung CA, Nankin HR, Blair SN. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994;140:930-7.
4. Lue T. Erectile dysfunction. N Engl J Med 2000;342:1802-13.
5. Salomon H, Man JW, Wierzbicki AS, Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 2003;91:230-1.
6. Cheitilin MD, Hutter AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999;99: 168-77.
7. Anderson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995;75:191-236.
8. Naylor AM. Endogenous neurotransmitters mediating penile erection. Br J Urol 1998;81:424-31.
9. Rajfer J, Aronson WJ, Bush PA, Dory FJ, Ignarro U. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90-4.
10. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75:725-48.
11. Product monograph. Uprima (apomorphine hydrochloride). http://www.uro.at/uprima/Monograph@20final.pdf, accessed April 19, 2003.
12. Goldestein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-404.
13. Brock GB, McMahon CG, Chen KK, Costigan T, Shei W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002:168:1332-6.
14. Thadani U, Smith W, Nash S, Bittar N, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002;40:2006-12.
15. FDA talk paper. March 27, 1998. FDA approves impotence pill, Viagra. http://www.fda.gov/bbs/topics/ANSWERS/ANS00857.html, accessed March 24, 2003.
16. Viagra (sildenafil citrate) tablets. Full prescribing information. http://www.viagra.com/professional/general/importantinfo.asp, accessed March 24, 2003.
17. Cialis (Tadalafil). Summary of product characteristics. http://www.lilly.co.uk/products/drugs.cfm?SPC_ID=384, accessed March 24, 2003.
18. Jackson G. Sexual intercourse and stable angina pectoris. Am J Cardiol 2000;86:35F-7F.
19. Bohlen JG, Held JP, Sanderson O, Patterson RP. Heart rate, rate-pressure product, and oxygen uptake during four sexual activities. Arch Intern Med 1984;144:1745-8.
20. Nemec ED, Mansfield L, Kennedy JW. Heart rate and blood pressure responses during sexual activity in normal males. Am Heart J 1976;92:274-7.
21. Hellerstein, HK, Friedman E. Sexual activity and the post coronary patient. Arch Intern Med 1970;125:987-99.
22. Fardy PS, Yanowitz FG. Evaluation and exercise prescription. In: Fardy PS, Yanowitz FG, eds. Cardiac rehabilitation adult fitness, and exercise testing. Baltimore: Williams & Wilkins, 1995: 251-2.
23. Drory Y, Shapira I, Fisman EZ, Pines A. Myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol 1995;75:835-7.
24. Master AM, Jaffee HL. Factors in the onset of coronary occlusion and coronary insufficiency: effort, occupation, trauma, and emotion. JAMA 1952;148:794.
25. Falk E. Why do plaques rupture? Circulation 1992;86:11130-42.
26. Muller JE, Mettleman A, Maclure M, Sheerwood JB, Tofler GH. Triggering acute myocardial infarction by sexual activity. JAMA 1996;275:1405-9.
27. Hagim AA, Petrovitch H, Burchfiel CM, et al. Effects of walking on mortality among nonsmoking retired men. N Engl J Med 1998; 338:94-9.
28. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease. 2001 update. Circulation 2001;104: 1577.
29. Morales A, Gingell C, Collins M, Osterloh IH. Clinical safety of oral sildenafil citrate (Viagra™) in the treatment of erectile dysfunction. Int J Impot Res 1998;10:69-74.
30. Padma-Nathan H, Steers WD, Wicker PA. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Pract 1998;52:375-80.
31. Herrmann HC, Chang G, Klugherz, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342:1622-6.
32. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil in men with known or probable coronary artery disease. A randomized crossover trial. JAMA 2002;287:719-25.
33. Bocchi EA, Guimaraes G, Mocelin A, Bacal F, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure. A double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002;106:1097-103.
34. Rendell, MS, Rajfer J, Wicker P, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes. A randomized controlled trial. JAMA 1999;281:421-6.
35. Geelen P, Drolet B, Rail J, Berube J, Daleau P, Rousseau G, Cardinal R, O'Hara GE, Turgeon J. Sildenafil (Viagra) prolongs cardiac repolarization by blockingthe rapid component of the delayed rectifier potassium current. Circulation 2000;102:275-7.
36. Piccirillo G, Nocco M, Lionetti M, Moise Antonio, Naso Camilla, Marigliano V, Cacciafesta M. Effects of sildenafil citrate (Viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J 2002;143:703-10.
37. Ishikura F, Beppu S, Hamada T, Khandherla BK, Seward JB, Nehra A. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation 2000;102:2516-21.
38. Webb DJ, Muirhead GJ, Wulf M, Sutton JA, Levi R, Dinsmore WW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable again. J Am Coll Cardiol 2000;36:25-31.
39. Diamond GA, Forester JS. Analysis of probability test as an aid in the clinical diagnosis of coronary artery disease. N Engl J Med 1979;300:1350-8.
40. Marwick TH. Safe sex for men with coronary artery disease. Exercise, sildenafil and risk for cardiovascular events. JAMA 2002; 287:766-7.
41. Fagan TC, Buttle S, Marbury T, Taylor A, Edmonds A, SL APO Study Group. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. Am J Cardiol 2001;88:760-6.
42. DeBusk R, Drory Y, Goldstein I, Jackson G, Kaul S, Kimmel SE, Kostis JB, Kloner RA, Lakin M, Meston CM, Mittleman M, Muller JE, Padma-Nathan H, Rosen RC, Stein RA, Zusman R. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000;86:62F-8F.
43. Larson JL, McNaughton MW, Kennedy JW, Mansfield LW. Heart rate and blood pressure responses to sexual activity and stair-climbing test. Heart Lung 1980;9:1025-30.
44. Arruda-Olson AM, Juracan EM, Mahoney DW, McCully RB, Roger VL, Pellikka PA. Prognostic value of exercise echocardiography in 5,798 patients. Is there a gender difference? J Am Coll Cardiol 2002;39:625-31.
45. Roger VL, Pellikka PA, Oh JK, Bailey KR, Tajik AJ. Identification of multivessel coronary artery disease by exercise echocardiogram. J Am Coll Cardiol 1994;24:109-14.
46. Gibbons RJ, Fyke E, Clements IP, Lapeyre AC, Zinmeister AR, Brown ML. Noninvasive identification of severe coronary artery disease using exercise radionuclide angiography. J Am Coll Cardiol 1988;11:28-34.
47. Stein RA. Cardiovascular responseto sexual activity. Am J Cardiol 2000;86:27F-9F.